MR imaging contrast agents — what's in a name?

The purpose of this brief review is to reduce the confusion surrounding the nomenclature of MRI contrast agents. There are several different categories of contrast agents for potential use in human diagnosis and several alternative names for each contrast agent, an array of choices that actually changes over time. This review describes the general process by which these various agents are named, presents one general categorization by which these agents can be considered, and provides a concise table to which readers can refer to identify the proper name to use for each of the agents that has thus far been administered to humans.

[1]  B. Marincek,et al.  Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. , 1995, Radiology.

[2]  B. Marincek,et al.  Oral superparamagnetic contrast agent (ferumoxsil): Tolerance and efficacy in MR imaging of gynecologic diseases , 1995, Journal of magnetic resonance imaging : JMRI.

[3]  M. Taupitz,et al.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.

[4]  B. V. Van Beers,et al.  Benign Hepatocellular Tumors: MRI After Superparamagnetic Iron Oxide Administration , 1995, Journal of computer assisted tomography.

[5]  R R Edelman,et al.  Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). , 1995, AJR. American journal of roentgenology.

[6]  H. Weinmann,et al.  Biodistribution and excretion of 153Gd-labeled gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid following repeated intravenous administration to rats. , 1995, Academic radiology.

[7]  Adrenal gland enhancement at MR imaging with Mn-DPDP. , 1995, Radiology.

[8]  I Narabayashi,et al.  Blueberry juice: preliminary evaluation as an oral contrast agent in gastrointestinal MR imaging. , 1995, Radiology.

[9]  M. Bernardino,et al.  Safety and optimum concentration of a manganese chloride–based oral MR contrast agent , 1994, Journal of magnetic resonance imaging : JMRI.

[10]  W. Yuh,et al.  Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. , 1994, Radiology.

[11]  M. Taupitz,et al.  Contrast‐enhanced MR imaging of liver and spleen: First experience in humans with a new superparamagnetic iron oxide , 1994, Journal of magnetic resonance imaging : JMRI.

[12]  A. Olukotun,et al.  Phase I clinical evaluation of a new iron oxide MR contrast agent , 1994, Journal of magnetic resonance imaging : JMRI.

[13]  A. Hatziioannou,et al.  A comparative study between Gd-DTPA and oral magnetic particles (OMP) as gastrointestinal (GI) contrast agents for MRI of the abdomen. , 1994, Magnetic resonance imaging.

[14]  S. Hauptmann,et al.  Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience. , 1993, Radiology.

[15]  Y. Ni,et al.  Mn-DPDP enhanced MRI in experimental bile duct obstruction. , 1993, Journal of computer assisted tomography.

[16]  C. McMahon,et al.  Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. , 1992, AJR. American journal of roentgenology.

[17]  M. Bernardino,et al.  Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. , 1992, Radiology.

[18]  F. Cavagna,et al.  Gd‐BOPTA/Dimeg: Experimental disease imaging , 1991, Magnetic resonance in medicine.

[19]  D. Mitchell,et al.  Comparison of Kaopectate with barium for negative and positive enteric contrast at MR imaging. , 1991, Radiology.

[20]  J. Mallada,et al.  MR and CT diagnosis of intracranial lipoma. , 1991, AJR. American journal of roentgenology.

[21]  L. Martí-Bonmatí,et al.  High density barium sulphate as an MRI oral contrast. , 1991, Magnetic resonance imaging.

[22]  R Weissleder,et al.  First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. , 1990, Radiology.

[23]  R. Weissleder,et al.  Clinical application of superparamagnetic iron oxide to MR imaging of tissue perfusion in vascular liver tumors. , 1990, Radiology.

[24]  L. Davidsson,et al.  Identification of transferrin as the major plasma carrier protein for manganese introduced orally or intravenously or after in vitro addition in the rat. , 1989, The Journal of nutrition.

[25]  G M Bydder,et al.  Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. , 1984, AJR. American journal of roentgenology.

[26]  R. Brasch,et al.  Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. , 1984, AJR. American journal of roentgenology.

[27]  G L Wolf,et al.  Cardiovascular toxicity and tissue proton T1 response to manganese injection in the dog and rabbit. , 1983, AJR. American journal of roentgenology.